This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Rochester Medical Discusses Q2 2011 Results -- Earnings Call Transcript

In short in the past year, we have more than quadrupled our combined US sales force. Last year, we had very limited sales coverage of the U.S. and essentially no regional sales management. Today, our sales force substantially covers the major US population centers, and our new regional managers help to better coordinate our sales efforts, both in existing accounts as well as in many new accounts. We firmly believe that all the upfront cost was considerable. This decision was prudent and necessary to growing our company and achieving our long-term financial growth. Now let turn it over to Dave for further details in the quarter.

Dave Jonas

Thanks Jim. I’m going to spend a few minutes highlighting the results reflected in our just released third quarter 2011 earnings. In this discussion, unless otherwise noted all sales information will be discussed in constant currency. I’m doing this to exclude the impact of foreign currency exchange in order to show a true reflection of our sales growth.

Foreign currency add approximately $350,000 to top line results for the third quarter and has added about $330,000 in the nine-month period. As Jim mentioned total sales rose 35% including Laprolan to $14.3 million from $10.2 million a year ago. Organic growth excluding Laprolan was in the lower double digits for the third quarter.

Total sales in the US increased 11% to $4.4 million from $3.9 million in the third quarter of 2010, driven by growth in both our US direct sales and our US private label business. Total sales outside of the US mainly in the Europe and Middle East region or EME grew 49% due to a very robust growth in direct sales and a combination of strong organic growth and Laprolan. This performance was partially offset by a decline international private label sales.

3 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 17,730.11 -27.80 -0.16%
S&P 500 2,076.78 -0.64 -0.03%
NASDAQ 5,009.2140 -3.9090 -0.08%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs